• Rocket One subsidiary Hoth Therapeutics will end its Phase 2a HT-001 trial early following strong interim efficacy results.
• Hoth plans to seek FDA feedback on a potential Phase 3 program; initiation depends on regulatory feedback and required development work.
• HT-001 targets skin toxicities associated with EGFR inhibitor cancer therapies. The treatment remains investigational.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket One Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030817PR_NEWS_USPR_____NY87411) on November 03, 2026, and is solely responsible for the information contained therein.